Business
Eterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on Ovarian Cancer and Autoimmune Disease
Ernexa Therapeutics embarks on new strategic direction, shifting the company’s focus from delivering a cell therapy platform to prioritizing product development New tagline to emphasize the company’s unwavering commitment to patient impact,“Breaking Through Defenses, Delivering Hope” CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics, a leader in cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the company’s new name: Ernexa Therap
About this update from Ernexa Therapeutics Inc.
[{"type":"text","content":"Ernexa Therapeutics embarks on new strategic direction, shifting the company’s focus from delivering a cell therapy platform to prioritizing product development","length":160,"tagName":"p"},{"type":"text","content":"New tagline to emphasize the company’s unwavering commitment to patient impact,“Breaking Through Defenses, Delivering Hope”","length":124,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics, a leader in cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the company’s new name: Ernexa TherapeuticsSM (NASDAQ: ERNA). The new name reflects the company’s laser-focused mission and ambitious vision.","length":319,"tagName":"p"},{"type":"text","content":"“Eterna Therapeutics began as a pioneer developing an innovative and differentiated cell therapy platform alone, but today, we have entered a new era of evolution and growth,” said Sanjeev Luther, President and CEO of Ernexa Therapeutics. “We are an organization with a new strategic focus, one that is advancing transformative cell therapy products with real clinical potential, directly impacting patients’ lives and addressing unmet medical needs.”","length":451,"tagName":"p"},{"type":"text","content":"Ernexa’s technology transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), which are a specialized type of stem cell that has a unique ability to migrate toward tumors or inflammation. Ernexa’s allogeneic synthetic iMSCs allow for enhanced predictability at scale, helping to avoid the challenges of immune rejection and donor shortages.","length":377,"tagName":"p"},{"type":"text","content":"Ernexa has two cell therapy products in development, which are undergoing preclinical trials. Its lead cell therapy product, ERNA-101, is engineered to enhance and regulate the immune system’s response, enabling it to identify and eliminate cancer cells. ERNA-102 is designed to combat inflammation and treat autoimmune disease.","length":328,"tagName":"p"},{"type":"text","content":"ERNA-101 is being developed for the treatment of ovarian cancer as its first indication. There is a significant unmet need in ovarian cancer, which currently lacks highly effective, widely applicable targeted therapies. Many patients develop resistance to the standard treatme...